株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

上気道感染症治療の世界市場:2020年~2024年

Global Upper Respiratory Tract Infection Treatment Market 2020-2024

発行 TechNavio (Infiniti Research Ltd.) 商品コード 934843
出版日 ページ情報 英文 120 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.72円で換算しております。
上気道感染症治療の世界市場:2020年~2024年 Global Upper Respiratory Tract Infection Treatment Market 2020-2024
出版日: 2020年05月02日 ページ情報: 英文 120 Pages
概要

世界の上気道感染症治療市場は、2020年から2024年の予測期間中に3%のCAGRで成長し、17億9,000万米ドルの規模に達する見込みです。当市場は、上気道感染症の発生率と有病率の上昇、有利な薬剤パイプライン、および市販薬の需要の増加まりなどが主な成長要因となっています。

当レポートでは、世界の上気道感染症治療市場について調査分析し、市場規模および成長率、市場動向、市場促進要因、課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

エグゼクティブサマリー

市場情勢

市場規模

  • 市場の定義
  • 市場セグメント分析
  • 2019年の市場規模
  • 市場の見通し:2019年から2024年の予測

ファイブフォース分析

タイプ別市場セグメンテーション

  • 市場セグメンテーション
  • タイプ別比較:市場規模・予測(2019年~2024年)
  • 抗生物質
  • NSAIDsと鼻充血除去薬
  • その他
  • タイプ別の市場機会

顧客情勢

地域別情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模・予測(2019年~2024年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 地域別市場機会
  • 数量的成長要因-需要主導型成長
  • 市場の課題
  • 市場動向

ベンダー情勢

  • ベンダー情勢
  • 情勢の革新
  • 競合シナリオ

ベンダー分析

  • 対象ベンダー
  • ベンダーの市場ポジショニング
  • AstraZeneca Plc
  • CSL Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

付録

目次
Product Code: IRTNTR43396

Technavio has been monitoring the upper respiratory tract infection treatment market and it is poised to grow by $ 1.79 billion during 2020-2024 progressing at a CAGR of 3% during the forecast period. Our reports on upper respiratory tract infection treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the rising incidence and prevalence of upper respiratory tract infections, favourable drug pipeline, and rising demand for over-the-counter drugs. In addition, rising incidence and prevalence of upper respiratory tract infections is anticipated to boost the growth of the market as well.

The upper respiratory tract infection treatment market analysis includes type segment and geographic landscapes

Technavio's ‘ upper respiratory tract infection treatment market ’ is segmented as below:

By Type:

  • Antibiotics
  • NSAIDs and nasal decongestants
  • others

By Geographic Landscape:

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the increasing R&D on upper respiratory tract infection treatment as one of the prime reasons driving the upper respiratory tract infection treatment market growth during the next few years. Also, emergence of biologics, and development of drug delivery devices to treat upper respiratory tract infections will lead to sizable demand in the market.

"Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our upper respiratory tract infection treatment market covers the following areas:

  • Upper respiratory tract infection treatment market sizing
  • Upper respiratory tract infection treatment market forecast
  • Upper respiratory tract infection treatment market industry analysis"

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading upper respiratory tract infection treatment market vendors that include AstraZeneca Plc, CSL Ltd., GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.. Also, the upper respiratory tract infection treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Antibiotics - Market size and forecast 2019-2024
  • NSAIDs and nasal decongestants - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by Type

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume driver - demand led growth
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption
  • Competitive scenario

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AstraZeneca Plc
  • CSL Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline Plc
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ billion)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Type - Market share 2019-2024 (%)
  • 22: Comparison by Type
  • 23: Antibiotics - Market size and forecast 2019-2024 ($ billion)
  • 24: Antibiotics - Year-over-year growth 2019-2024 (%)
  • 25: NSAIDs and nasal decongestants - Market size and forecast 2019-2024 ($ billion)
  • 26: NSAIDs and nasal decongestants - Year-over-year growth 2019-2024 (%)
  • 27: Others - Market size and forecast 2019-2024 ($ billion)
  • 28: Others - Year-over-year growth 2019-2024 (%)
  • 29: Market opportunity by Type
  • 30: Customer landscape
  • 31: Market share by geography 2019-2024 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2019-2024 ($ billion)
  • 34: North America - Year-over-year growth 2019-2024 (%)
  • 35: Europe - Market size and forecast 2019-2024 ($ billion)
  • 36: Europe - Year-over-year growth 2019-2024 (%)
  • 37: Asia - Market size and forecast 2019-2024 ($ billion)
  • 38: Asia - Year-over-year growth 2019-2024 (%)
  • 39: ROW - Market size and forecast 2019-2024 ($ billion)
  • 40: ROW - Year-over-year growth 2019-2024 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ billion)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: AstraZeneca Plc - Overview
  • 50: AstraZeneca Plc - Business segments
  • 51: AstraZeneca Plc - Key offerings
  • 52: AstraZeneca Plc - Key customers
  • 53: AstraZeneca Plc - Segment focus
  • 54: CSL Ltd. - Overview
  • 55: CSL Ltd. - Business segments
  • 56: CSL Ltd. - Key offerings
  • 57: CSL Ltd. - Key customers
  • 58: CSL Ltd. - Segment focus
  • 59: GlaxoSmithKline Plc - Overview
  • 60: GlaxoSmithKline Plc - Business segments
  • 61: GlaxoSmithKline Plc - Key offerings
  • 62: GlaxoSmithKline Plc - Key customers
  • 63: GlaxoSmithKline Plc - Segment focus
  • 64: Merck & Co. Inc. - Overview
  • 65: Merck & Co. Inc. - Business segments
  • 66: Merck & Co. Inc. - Key offerings
  • 67: Merck & Co. Inc. - Key customers
  • 68: Merck & Co. Inc. - Segment focus
  • 69: Novartis AG - Overview
  • 70: Novartis AG - Business segments
  • 71: Novartis AG - Key offerings
  • 72: Novartis AG - Key customers
  • 73: Novartis AG - Segment focus
  • 74: Pfizer Inc. - Overview
  • 75: Pfizer Inc. - Business segments
  • 76: Pfizer Inc. - Key offerings
  • 77: Pfizer Inc. - Key customers
  • 78: Pfizer Inc. - Segment focus
  • 79: Regeneron Pharmaceuticals Inc. - Overview
  • 80: Regeneron Pharmaceuticals Inc. - Business segments
  • 81: Regeneron Pharmaceuticals Inc. - Key offerings
  • 82: Regeneron Pharmaceuticals Inc. - Key customers
  • 83: Regeneron Pharmaceuticals Inc. - Segment focus
  • 84: Sanofi - Overview
  • 85: Sanofi - Business segments
  • 86: Sanofi - Key offerings
  • 87: Sanofi - Key customers
  • 88: Sanofi - Segment focus
  • 89: Teva Pharmaceutical Industries Ltd. - Overview
  • 90: Teva Pharmaceutical Industries Ltd. - Business segments
  • 91: Teva Pharmaceutical Industries Ltd. - Key offerings
  • 92: Teva Pharmaceutical Industries Ltd. - Key customers
  • 93: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 94: Currency conversion rates for US$
  • 95: Research Methodology
  • 96: Validation techniques employed for market sizing
  • 97: Information sources
  • 98: List of abbreviations